The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Srdan Verstovsek
Research Funding - Incyte
Jean-Jacques Kiladjian
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Martin Griesshammer
No relevant relationships to disclose
Tamás Masszi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Simon T. S. Durrant
Research Funding - Novartis
Francesco Passamonti
Consultant or Advisory Role - Novartis (U)
Claire N. Harrison
Honoraria - Novartis
Research Funding - Novartis
Fabrizio Pane
No relevant relationships to disclose
Pierre Zachee
No relevant relationships to disclose
Ruben A. Mesa
Research Funding - Incyte
Shui He
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Mark Jones
Employment or Leadership Position - Incyte
William M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jingjin Li
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ulrich Pirron
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tomasz Lawniczek
Employment or Leadership Position - Novartis
Alessandro M Vannucchi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis